Monoclonal peak on electrophoresis (monoclonal gammopathy, MGUS)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Warning signs (CRAB, tumour syndrome): urgent haematology advice
- No further tests in the community before the opinion: haematologist quickly.
- Bone pain, deterioration in general condition, lymphadenopathy, anaemia, hypercalcaemia, renal failure, bone lesions, hyperviscosity.
IgG or IgA peak (e.g. IgG lambda): first-line tests
Laboratory tests
- FBC
- Serum calcium (to be corrected for albumin or for total protein from the electrophoresis)
- Serum albumin (to interpret serum calcium)
- Serum creatinine with eGFR
- Urine protein:creatinine ratio (spot sample)
- Serum protein immunofixation (if the peak has not yet been typed)if neededPeak seen on electrophoresis but not characterised: the laboratory normally types it on its own initiative; unnecessary if the isotype is known [2,7].
- Urine protein electrophoresis (on the same sample as the urine protein:creatinine ratio)
- Serum immunoglobulins (IgG, IgA, IgM) (if recurrent infections)if neededRecurrent bacterial infections: looking for a fall in residual polyclonal immunoglobulins, the only use of this test according to the HAS; it does not measure the peak [2].
- Serum free light chains kappa and lambda, with ratioif neededTo complete the Mayo Clinic risk score [8]; specialist prescription according to the HAS, not reimbursed in primary care in France [2,9].
- NT-proBNP (at the slightest doubt of cardiac involvement)if neededSuspected cardiac involvement suggesting AL amyloidosis (dyspnoea, lower-limb oedema): NT-proBNP indicated according to the IFM (French Myeloma Intergroup) [3].
Do not order
- Bence Jones proteinuria in the presence of a serum peak: should not be requested according to the HAS [2]; the French laboratory fee schedule (NABM) provides for it only if proteinuria is > 50 mg/L or after the laboratory has typed a peak [7]. The IFM considers it unnecessary as a first-line test (test not reimbursed in France) [3].
- Serum immunoglobulins to quantify or monitor the peak: they do not measure the monoclonal immunoglobulin, only residual polyclonal immunoglobulins [2].
- Serum free light chains in primary care, as a routine test: second-line specialist prescription, not reimbursed in primary care in France [2]; routine measurement “not validated” according to the IFM [3].
- Beta-2-microglobulin in the presence of a monoclonal peak: unnecessary in primary care according to the IFM [3].
- Urine dipstick in place of a spot-sample urine protein test: not sufficient [3].
IgM peak: first-line tests
Laboratory tests
- FBC
- LDH
- Serum creatinine with eGFR
- Urine protein:creatinine ratio (spot sample)
- Urine protein electrophoresis (on the same sample as the urine protein:creatinine ratio)
- Serum calciumif neededThe IFM (2024) asks for serum calcium and albumin in any peak, without distinguishing the isotype [3]; the HAS asks for LDH and not calcium for an IgM peak [2].
- Serum albumin (IFM list, not requested by the HAS for an IgM peak)if neededThe IFM (2024) asks for serum calcium and albumin in any peak, without distinguishing the isotype [3]; the HAS asks for LDH and not calcium for an IgM peak [2].
Do not order
- Bence Jones proteinuria in the presence of a serum peak: should not be requested according to the HAS [2]; the French laboratory fee schedule (NABM) provides for it only if proteinuria is > 50 mg/L or after the laboratory has typed a peak [7]. The IFM considers it unnecessary as a first-line test (test not reimbursed in France) [3].
- Serum immunoglobulins to quantify or monitor the peak: they do not measure the monoclonal immunoglobulin, only residual polyclonal immunoglobulins [2].
- Beta-2-microglobulin in the presence of a monoclonal peak: unnecessary in primary care according to the IFM [3].
Monitoring of MGUS (without warning signs)
At 6 months, then every year (same laboratory)
- Serum protein electrophoresis
- FBC
- Serum creatinine with eGFR
- Urine protein:creatinine ratio (spot sample)
- Serum calcium (IgG or IgA peak)if neededIgG or IgA peak: risk of progression to myeloma [2].
- LDH (IgM peak)if neededIgM peak: risk of progression mainly to Waldenström disease [2].
- Serum albumin (with serum calcium)if neededIFM monitoring list, which combines serum albumin and calcium [3]; useful for interpreting the serum calcium of an IgG or IgA peak [2].
Do not order
- Immunofixation at every follow-up test: repeating the characterisation of the monoclonal immunoglobulin is unnecessary during follow-up [2].
Sources (16)
- Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood. 2018;131(2):163-173.
- Haute Autorité de santé. Fiche mémo : Quand prescrire une électrophorèse des protéines sériques (EPS) et conduite à tenir en cas d'une immunoglobuline monoclonale. Janvier 2017 (version mise à jour avec la mention de novembre 2025 sur la VS).
- Vincent L, Roussel M, Macro M, Karlin L, Vekemans MC, Royer B, Kuhnowski F, Meuleman N, Rey P, Arnulf B, Fermand JP, Decaux O (Intergroupe francophone du myélome). Pic monoclonal à l'électrophorèse. En pratique, qu'en faire en médecine générale ? Hématologie. 2024;30(1):71-88 ; republié dans Rev Prat Med Gen. 2025;39(1093):37-40.
- Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802-1824 (tableau 1 : critères diagnostiques de l'International Myeloma Working Group).
- National Institute for Health and Care Excellence (NICE). Suspected cancer: recognition and referral. Guideline NG12, juin 2015, mise à jour 15 avril 2026. Recommandations 1.10.4 et 1.10.5 (myélome, modifiées en 2025).
- NHS Lothian. RefHelp : Paraprotein (haematology referral guideline), version de juin 2023, page modifiée le 31 août 2023.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 du 2 juin 2026 : actes 0570, 1571 et 1619.
- Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812-817.
- Haute Autorité de santé. Dosage sérique des chaînes légères libres kappa et lambda dans les gammapathies monoclonales : note de cadrage. Juillet 2024.
- Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121-1127.
- Stern S, Chaudhuri S, Drayson M, Henshaw S, Karunanithi K, Willis F ; Haemato-Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum. Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper. Br J Haematol. 2023;202(4):734-744 (recommandations principales reprises dans le modèle d'audit de la BSH, hébergé par le Royal College of Pathologists).
- National Institute for Health and Care Excellence (NICE). Myeloma: diagnosis and management. Guideline NG35, février 2016, mise à jour 25 octobre 2018. Recommandations 1.2.
- Scheid C, Agis H, Driessen C, Hegenbart U, Knop ST, Krauth MT, Naumann R, Schieferdecker A, Schwotzer R, Weisel K. Monoklonale Gammopathie unklarer Signifikanz (MGUS). Onkopedia, recommandation de la DGHO (société allemande d'hématologie et d'oncologie, avec les sociétés autrichienne et suisse), état septembre 2026.
- Khouri J, Samaras C, Valent J, Mejia Garcia A, Faiman B, Mathur S, Hamilton K, Nakashima MO, Kalaycio M. Monoclonal gammopathy of undetermined significance: A primary care guide. Cleve Clin J Med. 2019;86(1):39-46.
- Royal United Hospitals Bath NHS Foundation Trust. Monoclonal gammopathy of undetermined significance (MGUS): a guide for GPs. Document HAEM-014, version 3.0, approuvée le 30 septembre 2026.
- Myeloma UK. Myeloma, MGUS and related conditions: a guide for GPs. Août 2023.